The management of unresectable and metastatic cutaneous melanoma has substantially improved with the introduction of molecular targeted therapy (BRAF and MEK inhibitors) and immunotherapy (Immune checkpoint inhibitors). Here, MAP2K7 is linked to cutaneous melanoma.